Satia M C, Shukla M L, Goyal R K
Department of Pharmacology, L. M. College of Pharmacy, Ahmedabad.
Indian J Physiol Pharmacol. 1995 Jul;39(3):237-41.
A controlled clinical trial on 65 patients was performed to compare the effects of nifedipine and atenolol in diabetic and non-diabetic hypertensive patients. Patients were from 45 to 70 years in age. The diabetic hypertensive patients and non-diabetic essential hypertensive patients randomly received atenolol (50-100 mg per day) or nifedipine (10-20 mg per day) for 9 months. Both the drugs effectively controlled the blood pressure throughout the therapy. Atenolol treatment significantly increased triglyceride levels and decreased the HDL-cholesterol levels after 9 months in both groups. However, nifedipine therapy did not alter lipid levels to any significant extent. Both drugs did not alter blood glucose, serum creatinine and blood urea levels. It may be concluded from the present study that nifedipine is preferable to atenolol as it does not alter lipid profile to any significant extent in diabetic and non-diabetic hypertensive patients.
对65名患者进行了一项对照临床试验,以比较硝苯地平和阿替洛尔对糖尿病和非糖尿病高血压患者的疗效。患者年龄在45至70岁之间。糖尿病高血压患者和非糖尿病原发性高血压患者随机接受阿替洛尔(每日50 - 100毫克)或硝苯地平(每日10 - 20毫克)治疗9个月。在整个治疗过程中,两种药物均有效控制了血压。9个月后,阿替洛尔治疗在两组中均显著提高了甘油三酯水平并降低了高密度脂蛋白胆固醇水平。然而,硝苯地平治疗在任何显著程度上均未改变血脂水平。两种药物均未改变血糖、血清肌酐和血尿素水平。从本研究可以得出结论,硝苯地平比阿替洛尔更可取,因为它在糖尿病和非糖尿病高血压患者中不会在任何显著程度上改变血脂谱。